2023
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53
Siddon A, Weinberg O. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53. Clinics In Laboratory Medicine 2023, 43: 607-614. PMID: 37865506, DOI: 10.1016/j.cll.2023.07.004.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeTP53 mutationsPrognosis of MDSCases of MDSPrognostic scoring systemNext-generation sequencingParticular next-generation sequencingAggressive diseasePoor outcomeTherapeutic managementTP53 disruptionMyeloid leukemiaMyeloid neoplasmsTherapeutic advancementsCytogenetic abnormalitiesMyeloid neoplasiaScoring systemDisease classificationMyeloid diseasesGene mutationsSyndromeDiseaseDiagnosisTP53
2022
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Weinberg OK, Siddon A, Madanat Y, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Advances 2022, 6: 2847-2853. PMID: 35073573, PMCID: PMC9092405, DOI: 10.1182/bloodadvances.2021006239.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeOverall survivalTP53 mutationsComplex karyotypeBlast countWorse outcomesTherapy-related MDS/acute myeloid leukemiaDiagnosis of AMLMDS/acute myeloid leukemiaTherapy-related myeloid neoplasmsTherapy-related casesTP53-mutated patientsDe novo diseaseMarrow blast countLower hemoglobin levelsWorse overall survivalCK patientsNovo diseaseDifferent disease categoriesClinicopathologic featuresHemoglobin levelsMDS patientsMultivariable analysisAggressive disease